Prevalence of transmitted HIV-1 drug resistance and the role of resistance algorithms: Data from seroconverters in the CASCADE collaboration from 1987 to 2003

Journal of Acquired Immune Deficiency Syndromes

Volumn 40, Issue 5, 2005, Pages 505-511

  Masquelier, Bernard ^a   Bhaskaran, Krishnan ^b   Pillay, Deenan ^c   Gifford, Robert ^c   Balestre, Eric ^d   Jørgensen, Louise Bruun ^e   Pedersen, Court ^f   Van Der Hoek, Lia ^g   Prins, Maria ^h   Balotta, Claudia ⁱ   Longo, Benedetta ^j   Kücherer, Claudia ^k   Poggensee, Gabriele ^k   Ortiz, Marta ^l   De Mendoza, Carmen ^m   Gill, John ⁿ   Fleury, Hervé ^a   Porter, Kholoud ^b  

^a BORDEAUX UNIVERSITY HOSPITAL   (France)

^b MRC CLINICAL TRIALS UNIT   (United Kingdom)

^c ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^d INSERM   (France)

^e STATENS SERUM INSTITUT   (Denmark)

^f ODENSE UNIVERSITY HOSPITAL   (Denmark)

^g ACADEMIC MEDICAL CENTER   (Netherlands)

^h MUNICIPAL HEALTH SERVICE   (Netherlands)

ⁱ UNIVERSITY OF MILAN   (Italy)

^j ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^k ROBERT KOCH INSTITUTE   (Germany)

^l Servicio de Diagnostico Y Referencia de Retrorivirus   (Spain)

^m HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

ⁿ Southern Alberta HIV Clinic   (Canada)

more..

Author keywords

Genotype; HIV 1 drug resistance; HIV 1 transmission; Prevalence of resistance

Indexed keywords

ANTIVIRUS AGENT;

ALGORITHM; ARTICLE; CANADA; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; EUROPE; FEMALE; GENE MUTATION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFORMATION PROCESSING; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PRIORITY JOURNAL; RISK FACTOR; SEROCONVERSION; VIRUS RESISTANCE; VIRUS TRANSMISSION;

EID: 27944503360     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.qai.0000186361.42834.61     Document Type: Article

References (33)

1. Hirsch MS, Brun-Vezinet F, Clotet B, et al. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. Clin Infect Dis. 2003;37:113-128.
2. Erice A, Mayers DL, Strike DG, et al. Brief report: primary infection with zidovudine-resistant human immunodeficiency virus type 1. N Engl J Med. 1993;328:1163-1165.
3. Conlon CP, Klenerman P, Edwards A, et al. Heterosexual transmission of human immunodeficiency virus type 1 variants associated with zidovudine resistance. J Infect Dis. 1994;169:411-415.
4. Mayers DL. Prevalence and incidence of resistance to zidovudine and other antiretroviral drugs. Am J Med. 1997;102:70-75.
5. Masquelier B, Chaix ML, Burgard M, et al, for the French Pediatric HIV Infection Study Group. Zidovudine genotypic resistance in HIV-1-infected newborns in the French perinatal cohort. J Acquir Immune Defic Syndr. 2001;27:99-104.
6. Caride E, Brindeiro RM, Kallas EG, et al. Sexual transmission of HIV-1 isolate showing G→A hypermutation. J Clin Virol. 2002;23:179-189.
7. Leigh Brown AJ, Frost SD, Mathews WC, et al. Transmission fitness of drug-resistant human immunodeficiency virus and the prevalence of resistance in the antiretroviral-treated population. J Infect Dis. 2003;187:683-686.
8. Nijhuis M, Schuurmann R, de Jong D, et al. Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy. AIDS. 1999;13:2349-2359.
9. Collaborative UK Group on Monitoring the Transmission of HIV Drug Resistance. Analysis of prevalence of HIV-1 drug resistance in primary infections in the United Kingdom. BMJ. 2001;322:1087-1088.
10. Little SJ. Transmission and prevalence of HIV resistance among treatment-naive subjects. Antivir Ther. 2000;5:33-40.
11. Balotta C, Berlusconi A, Pan A, et al. Prevalence of transmitted nucleoside analogue-resistant HIV-1 strains and pre-existing mutations in pol reverse transcriptase and protease region: outcome after treatment in recently infected individuals. Antivir Ther. 2000;5:7-14.
12. Little SJ, Holte S, Routy JP, et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med. 2002;347:385-394.
13. Chaix ML, Descamps D, Harzic M, et al. Stable prevalence of genotypic drug resistance mutations but increase in non-B virus among patients with primary HIV-1 infection in France. AIDS. 2003;17:2635-2643.
14. Yerly S, Kaiser L, Race E, et al. Transmission of antiretroviral-drug- resistant HIV-1 variants. Lancet. 1999;354:729-733.
15. Yerly S, Jost S, Telenti A, et al. Swiss HIV Cohort Study. Infrequent transmission of HIV-1 drug-resistant variants. Antivir Ther. 2004;9:375-384.
16. Bezemer D, Jurriaans S, Prins M, et al. Declining trend in transmission of drug-resistant HIV-1 in Amsterdam. AIDS. 2004;18:1571-1577.
17. Simon V, Vanderhoeven J, Hurley A, et al. Evolving patterns of HIV-1 resistance to antiretroviral agents in newly infected individuals. AIDS. 2002;16:1511-1519.
18. Weinstock HS, Zaidi I, Heneine W, et al. The epidemiology of antiretroviral drug resistance among drug-naive HIV-1-infected persons in 10 US cities. J Infect Dis. 2004;189:2174-2180.
19. Wensing AM, Boucher CA. Worldwide transmission of drug-resistant HIV. AIDS Rev. 2003;5:140-155.
20. Grossman Z, Lorber M, Maayan S, et al. Drug-resistant HIV infection among drug-naive patients in Israel. Clin Infect Dis. 2005;40:294-302.
21. Bennett D, McCormick L, Kline R, et al, and the HIV Drug Resistance ARVDRT/VARHS Surveillance Group. U.S. surveillance of HIV drug resistance at diagnosis using HIV diagnostic sera. Abstract 674. Paper presented at: 12th Conference on Retroviruses and Opportunistic Infections; February 22-25, 2005; Boston, MA.
22. de Mendoza C, Rodriguez C, Colomina J, et al, on behalf of the Spanish Seroconverter Study Group. Transmission of drug-resistant viruses in recent HIV seroconverters in Spain. Abstract 672. Paper presented at: 12th Conference on Retroviruses and Opportunistic Infections; February 22-25, 2005; Boston, MA.
23. Hicks C, Eron J, Fiscus S, et al. Transmitted HIV resistance among patients with acute and recent HIV infection in North Carolina: report of 102 cases. Abstract 673. Paper presented at: 12th Conference on Retroviruses and Opportunistic Infections; February 22-25, 2005; Boston, MA.
24. Richman DD, Morton SC, Wrin T, et al. The prevalence of antiretroviral drug resistance in the United States. AIDS. 2004;18:1393-1401.
25. Tamalet C, Fantini J, Tourres C, et al. Resistance of HIV-1 to multiple antiretroviral drugs in France: a 6-year survey (1997-2002) based on an analysis of over 7000 genotypes. AIDS. 2003;17:2383-2388.
26. Scott P, Arnold E, Evans B, et al. Surveillance of HIV antiretroviral drug resistance in treated individuals in England: 1998-2000. J Antimicrob Chemother. 2004;53:469-473.
27. CASCADE Collaboration. Changes in the uptake of antiretroviral therapy and survival in persons with known duration of HIV infection in Europe. HIV Med. 2000;1:224-231.
28. Posada D, Crandall KA. MODELTEST: testing the model of DNA substitution. Bioinformatics. 1998;14:817-818.
29. Wensing AMJ, Van de Vijver DAMC, Asjo B, et al. Prevalence of transmitted drug resistance in Europe is largely influenced by the presence of non-B sequences: analysis of 1400 patients from 16 countries: the CATCH-Study. Antivir Ther. 2003;8:S131.
30. Salomon H, Wainberg MA, Brenner B, et al. Prevalence of HIV-1 resistant to antiretroviral drugs in 81 individuals newly infected by sexual contact or injecting drug use. Investigators of the Quebec Primary Infection Study. AIDS. 2000;14:F17-F23.
31. Routy JP, Machouf N, Edwardes MD, et al. Factors associated with a decrease in the prevalence of drug resistance in newly HIV-1 infected individuals in Montreal. AIDS. 2004;18:2305-2312.
32. Descamps D, Chaix ML, Andre P, et al. French national sentinel survey of antiretroviral drug resistance in patients with HIV-1 primary infection and in antiretroviral naive chronically infected patients in 2001-2002. J Acquir Immune Defic Syndr. 2005;38:545-552.
33. Pao D, Fisher M, Hue S, et al. Transmission of HIV-1 during primary infection: relationship to sexual risk and sexually transmitted infections. AIDS. 2005;19:85-90.